Evidence map›Paper›PMID 33222603›Full record

ArticleGut microbes2020

Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity.

Xiao-Yu Zhang, Jiang Chen, Kang Yi, Ling Peng, Jie Xie, Xun Gou, Tong Peng, Lin Tang

Open access · goldAbstract read
In one paragraph

Article in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 242 citations in OpenAlex.

  1. Pooled it
  2. Understanding the gut microbiota and sarcopenia: a systematic review.Journal of cachexia, sarcopenia and muscle · 2021
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Journal of microbiology and biotechnology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Multidimensional Profiling of Chinese Sweet TeaFoods (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Review

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiao-Yu ZhangCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Jiang ChenCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Kang YiCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Ling PengCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Jie XieCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Xun GouCollege of Life Sciences, Sichuan Normal University , Chengdu, P.R. China.
Tong PengR&D Department, Keystonecare Technology (Chengdu) Co., Ltd , Chengdu, P.R. China.
Lin TangCollege of Life Sciences, Sichuan University , Chengdu, P.R. China.
Sichuan Normal University · CNChinese Academy of Sciences · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phlorizin (PHZ) is one of phytonutrients in apples that contributes to the health-promoting effect implicated by the saying, 'an apple a day keeps the doctor away'. PHZ was firstly identified as a competitive inhibitor of sodium-glucose co-transporters-2 (SGLT2); however, its low bioavailability makes it hard to fully explain its pharmacological mechanisms. This study aimed to investigate the ameliorating effect of PHZ on high-fat diet (HFD)-induced obesity via modulating the "gut microbiota-barrier axis". Firstly, C57BL/6 J mice were fed a normal chow diet (NCD) or HFD coadministered with or without PHZ for 12 weeks. Our results showed that PHZ supplementation significantly reduced HFD-induced body weight gain (

Indexed as

AnimalsAnti-Obesity AgentsBacteriaDietary SupplementsDiet, High-FatEndotoxemiaFatty Acids, VolatileFecal Microbiota TransplantationGastrointestinal MicrobiomeInsulin ResistanceLipopolysaccharidesMaleMiceMice, Inbred C57BLObesityPhlorhizinAnti-Obesity AgentsFatty Acids, VolatileLipopolysaccharidesPhlorhizinPhytochemicalsbarrier integrityglucagon-like peptide 2 (GLP-2)gut microbiotaobesityPhlorizin (PHZ)short-chain fatty acids (SCFAs)

Identifiers

PMID33222603
PMCPMC7714487
OpenAlexW3107645065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.